These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30984937)

  • 1. Modular design of nanobody-drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent.
    Huang H; Wu T; Shi H; Wu Y; Yang H; Zhong K; Wang Y; Liu Y
    Chem Commun (Camb); 2019 Apr; 55(35):5175-5178. PubMed ID: 30984937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation.
    Li L; Zhu Y; Liu M; Jin D; Zhang L; Cheng J; Liu Y
    J Inorg Biochem; 2021 Oct; 223():111553. PubMed ID: 34340059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
    Fang T; Ye Z; Wu J; Wang H
    Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clustered nanobody-drug conjugates for targeted cancer therapy.
    Wu T; Liu M; Huang H; Sheng Y; Xiao H; Liu Y
    Chem Commun (Camb); 2020 Aug; 56(65):9344-9347. PubMed ID: 32672289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF; Wong DY; Jothibasu R; Ang WH
    Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H; Cheng Q; Yuan S; Ding X; Liu Y
    Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
    Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment.
    Lim WQ; Phua SZF; Chen H; Zhao Y
    Chem Commun (Camb); 2018 Nov; 54(90):12762-12765. PubMed ID: 30370905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Nanobody-Conjugated DNA Nanoplatform for Targeted Platinum-Drug Delivery.
    Wu T; Liu J; Liu M; Liu S; Zhao S; Tian R; Wei D; Liu Y; Zhao Y; Xiao H; Ding B
    Angew Chem Int Ed Engl; 2019 Oct; 58(40):14224-14228. PubMed ID: 31389144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F; Pei S; Wang X; Zhu Q; Gou S
    Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
    Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.
    Xiao H; Song H; Zhang Y; Qi R; Wang R; Xie Z; Huang Y; Li Y; Wu Y; Jing X
    Biomaterials; 2012 Nov; 33(33):8657-69. PubMed ID: 22938766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
    Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards rational design of RAD51-targeting prodrugs: platinum
    Zhang S; Yuan H; Guo Y; Wang K; Wang X; Guo Z
    Chem Commun (Camb); 2018 Oct; 54(83):11717-11720. PubMed ID: 30229259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
    J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.